FDA Launches Rare Disease Framework Initiative to Reimagine Drug Development for Small Patient Populations

The FDA has announced the Rare Disease Framework Initiative, a broad effort to build a new regulatory approach tailored specifically to the challenges of developing drugs and biologics for rare diseases.¹

The initiative, led by the FDA’s Rare Disease Innovation Hub, is accompanied by a white paper released today and will begin with a public meeting at the FDA’s White Oak campus on October 28, facilitated by the Reagan-Udall Foundation for the FDA.

The scale of the problem the initiative is designed to address is significant. Approximately 30 million Americans, roughly one in ten, live with a rare disease, and the affected global population reaches an estimated 300 million people across 7,000 to 10,000 distinct conditions. Despite that scale, only approximately 5% of recognized rare diseases have an FDA-approved treatment.

The absence of approved therapies is not a neutral baseline: research cited in the white paper found that lacking an approved treatment is independently associated with a 21.2% annual increase in total per-patient costs.²

“Patients and families living with rare diseases have few or no approved treatment options, and the burden of uncertainty can extend across every part of their lives,” said Acting FDA Commissioner Kyle Diamantas, JD, in an agency press release. “The FDA will fight hard for patients by building a more consistent, predictable, and innovative approach to rare disease drug development while maintaining the rigorous standards Americans expect from the FDA.

Why existing approaches fall short

The white paper is clear on why current frameworks are inadequate for rare disease settings. Patient populations are small, sometimes numbering in the hundreds globally, and are often geographically dispersed, making clinical trial enrollment difficult. Natural history data, which forms the evidentiary foundation for trial design in common disease development, is frequently sparse or nonexistent. Biomarkers that could serve as surrogate endpoints may be non-validated or absent entirely. And disease heterogeneity, genetic, phenotypic, or both, can make it difficult to define a homogeneous study population.

These constraints have direct implications for trial design. The evidentiary tools routine in common disease development, including placebo-controlled trials and validated surrogate endpoints, may simply not be available in rare disease settings.

The white paper states that while regulatory flexibility exists and has been applied in many cases, it has not been applied consistently across review divisions, and that inconsistency is a core problem the framework is intended to fix.

The FDA notes that in recent years approximately half of novel approvals across the Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER) have been for rare diseases, and that a 2024 GAO report identified 18 rare disease programs at the agency, most launched since 2019. Despite those efforts, the 95% treatment gap has not meaningfully closed.

What the framework will do

The initiative is organized around six guiding principles: providing greater clarity and predictability in regulatory decision-making; embedding the patient voice early and at defined milestones in development and review; leveraging external expertise for customized regulatory review; building shared resources and institutional knowledge across review divisions; applying risk-based approaches to chemistry, manufacturing, and controls review and pre-approval inspections; and championing cutting-edge science and innovative statistical approaches.

Expected deliverables include potential revisions to existing regulations, systematic review and revision of guidance documents covering endpoints, statistical approaches, and trial design, alignment within CDER and CBER to improve consistency across review divisions, and a training plan to ensure reviewers can consistently apply the new framework.

“A bold vision to reimagine the framework for rare disease drug development that builds on key learnings and milestones is necessary to meet this moment,” said Amy Comstock Rick, JD, director of the FDA’s Rare Disease Innovation Hub, in the release. “This new framework will enhance consistency and predictability for both sponsors and for patients.”

Beyond the October 28 public meeting, the FDA plans sector-specific roundtables with drug developers, patient and disease advocacy organizations, academic researchers, and practicing clinicians, as well as a Federal Register Request for Information and internal feedback sessions with CDER and CBER review teams. That feedback will inform the detailed development of the framework, which may include new or revised guidance, regulatory changes, and organizational adjustments.

References

1. FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development. FDA. October 14, 2026. https://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease
2. A New Framework for Rare Disease Review. FDA. October 2026. https://www.fda.gov/media/195694/download?attachment